May 21st 2025
The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.
May 21st 2025
FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.
May 19th 2025
The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.
May 15th 2025
Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.
May 7th 2025
In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 Variants
October 4th 2024Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Watch
NFID Survey: Fewer Than 1 in 5 Americans Are Concerned About Respiratory Viruses
September 26th 2024The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.
Read More
Reassessing COVID-19 Treatments: Nirmatrelvir/Ritonavir and Molnupiravir Against New Variants
September 19th 2024Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.
Read More
New Data on Bemnifosbuvir's Progress in COVID-19 and HCV Trials
Published: September 3rd 2024 | Updated: September 3rd 2024Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.
Read More
Monoclonal Antibody Reduces Symptomatic COVID-19 Risk by 84% in Immunocompromised
Published: August 27th 2024 | Updated: August 27th 2024Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.
Read More
FDA Grants EUA for Updated mRNA COVID-19 Vaccines Targeting Omicron Variant KP2
August 22nd 2024The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.
Read More
Could a Nasal COVID-19 Vaccine Offer Differing Benefits to Subcutaneous Injections?
August 8th 2024A new phase 1 clinical trial will determine if vaccine candidate, MPV/S-2P, is safe for humans, and may potentially offer protection not seen before in the first-generation of COVID-19 vaccines.
Read More
2 Commerce Drive
Cranbury, NJ 08512